Nonacog Beta Pegol for Hemophilia B (paradigm™5 Trial)

"The study is not presently recruiting patients for participation. The listing was first posted on May 16th, 2012 and last updated on November 8th, 2020. There are other active clinical trials that might be of interest; 112 trials for hemophilia b and 1 trial for nonacog beta pegol are both open for recruitment."

"Following the study's inclusion criteria, patients that wish to participate must be between 0 and 12 years old."

"Perioperative blood loss, hemorrhage, and bleeding can all be effectively treated using nonacog beta pegol."

"There is clinical evidence to support the safety of nonacog beta pegol, thus it received a score of 3."

"Novo Nordisk Investigational Site first began to study nonacog beta pegol in 2012 and, since then, 6 trials have completed. Presently, there is 1 active trial with a considerable amount of the research taking place in Nashville, Tennessee."

"This haemophilia B clinical trial, which is looking for 25 participants, has several notable inclusion criteria. Most importantly, patients must be between 0 and 12 years old (at the time of inclusion), have a history of exposure to other FIX products (with at least 50 exposure days), be able to assess their own bleeds and keep track of them in an electronic diary, as well as being willing/able to follow all other trial procedures. In addition, candidates must weigh more than 10 kg and be male patients with moderately severe or worse congenital haemophilia B whose Factor IX activity levels are below 2% according to medical"

"Nov Nordisk A/S sponsored the first clinical trial for nonacog beta pegol in 2012 and, to date, 6 trials have been completed. The most recent study is still ongoing across 20 cities and 11 countries. This Phase 3 drug approval stage study involves 25 participants."